TACE or HAIC with immunotherapy and lenvatinib for liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares two standard treatments (TACE and HAIC) when combined with an immunotherapy drug (PD-1 inhibitor) and an oral targeted therapy (lenvatinib) for people with liver cancer that cannot be surgically removed. The goal is to see which approach works better in shrinking tumors and improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your liver cancer is newly diagnosed and you have not received any prior cancer treatment.
- Your liver cancer is at a stage where it has not spread to other organs (no distant metastasis).
- Your liver function is adequate (Child-Pugh score of 7 or less).
- You are in good general health (able to perform daily activities, ECOG 0-1).
- You do not have serious heart, lung, or brain diseases, and you do not have active autoimmune diseases or viral hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of treatments for liver cancer that has not been treated before and is linked to high pressure in the liver's blood vessels. The goal is to see if adding carvedilol to standard treatments can improve outcomes.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.